Magnetar Financial LLC Boosts Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Magnetar Financial LLC boosted its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 0.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 637,443 shares of the health services provider’s stock after purchasing an additional 1,835 shares during the quarter. Amedisys makes up approximately 1.4% of Magnetar Financial LLC’s holdings, making the stock its 20th largest holding. Magnetar Financial LLC’s holdings in Amedisys were worth $57,873,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. increased its holdings in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC purchased a new stake in Amedisys during the 4th quarter worth approximately $38,000. Versant Capital Management Inc increased its holdings in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV bought a new stake in shares of Amedisys in the 3rd quarter valued at approximately $63,000. Finally, Vestcor Inc bought a new stake in shares of Amedisys in the 4th quarter valued at approximately $73,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Price Performance

Shares of AMED opened at $92.89 on Thursday. The company has a market cap of $3.05 billion, a P/E ratio of 36.86, a PEG ratio of 1.78 and a beta of 0.76. The stock has a fifty day moving average price of $92.19 and a 200 day moving average price of $92.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. On average, research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.